Technion Research & Development Foundation Ltd

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Teva Pharmaceutical Industries Limited

Yacov Herzig

Jeffrey Sterling

Michael Chorev

Moussa B H Youdim

Marta Weinstock-Rosin

Tamar Goren

This invention is directed to compounds of the following formula:wherein when a is 0, b is 1 or 2; when a is 1, b is 1, m is from 0-3, X is O or S, Y is halogeno, Ris hydrogen Calkyl, Ris hydrogen, Calkyl, or optionally substituted propargyl and Rand Rare each independently hydrogen, Calkyl, Caryl, Caralkyl each optionally substituted. This invention is also directed to the use of these compounds for treating depression, Attention Deficit Disorder (ADD), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome, Alzheimer's Disease and other dementia's such as senile dementia, dementia of the Parkinson's type, vascular dementia and Lewy body dementia. This invention is further directed to a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Aminoindan derivatives

Growing community of inventors

Ra'ananna, Israel

Yacov Herzig